Zuellig Pharma Enhances Clinical Supply Capabilities in China with New Acquisition
Zuellig Pharma, one of Asia's premier healthcare solution providers, has made a significant move to bolster its clinical supply chain capabilities within China through the acquisition of a specialized clinical supply facility located in Hangzhou. This strategic acquisition, announced on November 3, 2026, underlines the company's commitment to enhancing local sourcing for clinical trials in an increasingly vital market for global healthcare initiatives.
The newly acquired Hangzhou facility is equipped with a Drug Distribution License (DDL), enabling Zuellig Pharma to efficiently source comparator drugs and concomitant medications required for clinical studies conducted in the region. This capability is a substantial upgrade for the company, allowing it to deliver compliant and efficient solutions for sponsors involved in clinical trials. Additionally, the acquisition is set to simplify billing processes while creating opportunities for savings through value-added tax (VAT) reductions—benefits that will significantly aid trial sponsors operating in the competitive healthcare landscape of China.
Situated in the Yangtze River Delta's biopharmaceutical innovation corridor, the Hangzhou site aligns perfectly with Zuellig Pharma’s existing infrastructure, seamlessly connecting to its Beijing depot and global network of over 45 clinical depots. This strategic location is essential for meeting the rising demand for clinical trial resources amid the rapid progression of healthcare developments in the region.
To ensure that products maintain their integrity throughout the supply chain, the Hangzhou facility boasts advanced cold-chain technologies and precise temperature controls. This enables the facility to accommodate a range of temperature-sensitive products, with capacities that can manage environments from 15°C to 25°C, 2°C to 8°C, and even as low as -20°C. Such technological advancements are crucial for preserving the quality of the pharmaceuticals involved in clinical studies.
John Graham, the Group Chief Executive Officer at Zuellig Pharma, articulated that "Asia is undeniably becoming a pivotal player in the realm of global clinical research and drug development, and China occupies a critical position within this landscape. This acquisition is a reflection of our unwavering commitment to invest in the necessary infrastructure to fulfill both regional and global healthcare demands. By enhancing our clinical trial support framework, we are empowering our partners to expedite the development of transformative therapies for patients throughout Asia and beyond."
The acquisition dovetails with the operational goals of Zuellig Pharma, which focuses on eliminating logistical challenges often associated with clinical development. Ensuring that vital supplies are delivered safely and efficiently to trial sites and patients is a priority for the company. In David Christmas's words, Executive Vice President of Distribution & Clinical Trial Support at Zuellig Pharma, the inclusion of the licensed Hangzhou facility marks a significant evolution in the company's ability to support clinical trials in China. He emphasizes that this advancement not only localizes sourcing and distribution capabilities but also enables smoother operation of domestic studies and multi-regional clinical trials (MRCTs) with diminished cycle times and strict adherence to regulatory obligations.
With a proven track record of serving as a trusted clinical logistics and sourcing partner to numerous pharmaceutical giants, Zuellig Pharma's Clinical Trial Support division collaborates with 29 out of the world's top 50 pharmaceutical companies and 18 out of the top 50 global Contract Research Organizations. This highlights the firm’s reputation as a provider of integrated end-to-end clinical supply chain solutions on a global scale.
In summary, Zuellig Pharma's latest acquisition of the Hangzhou facility not only strengthens its infrastructural capabilities but also reiterates the company’s ongoing dedication to building reliable, sustainable, and digitally enhanced clinical supply operations. This strategic move is set to propel the development of innovative medical therapies while improving access to healthcare solutions for regions served by the company. As the healthcare landscape continues to evolve, Zuellig Pharma stands at the forefront, guiding the future of clinical trials and pharmaceutical distribution in Asia and beyond.
The newly acquired Hangzhou facility is equipped with a Drug Distribution License (DDL), enabling Zuellig Pharma to efficiently source comparator drugs and concomitant medications required for clinical studies conducted in the region. This capability is a substantial upgrade for the company, allowing it to deliver compliant and efficient solutions for sponsors involved in clinical trials. Additionally, the acquisition is set to simplify billing processes while creating opportunities for savings through value-added tax (VAT) reductions—benefits that will significantly aid trial sponsors operating in the competitive healthcare landscape of China.
Situated in the Yangtze River Delta's biopharmaceutical innovation corridor, the Hangzhou site aligns perfectly with Zuellig Pharma’s existing infrastructure, seamlessly connecting to its Beijing depot and global network of over 45 clinical depots. This strategic location is essential for meeting the rising demand for clinical trial resources amid the rapid progression of healthcare developments in the region.
To ensure that products maintain their integrity throughout the supply chain, the Hangzhou facility boasts advanced cold-chain technologies and precise temperature controls. This enables the facility to accommodate a range of temperature-sensitive products, with capacities that can manage environments from 15°C to 25°C, 2°C to 8°C, and even as low as -20°C. Such technological advancements are crucial for preserving the quality of the pharmaceuticals involved in clinical studies.
John Graham, the Group Chief Executive Officer at Zuellig Pharma, articulated that "Asia is undeniably becoming a pivotal player in the realm of global clinical research and drug development, and China occupies a critical position within this landscape. This acquisition is a reflection of our unwavering commitment to invest in the necessary infrastructure to fulfill both regional and global healthcare demands. By enhancing our clinical trial support framework, we are empowering our partners to expedite the development of transformative therapies for patients throughout Asia and beyond."
The acquisition dovetails with the operational goals of Zuellig Pharma, which focuses on eliminating logistical challenges often associated with clinical development. Ensuring that vital supplies are delivered safely and efficiently to trial sites and patients is a priority for the company. In David Christmas's words, Executive Vice President of Distribution & Clinical Trial Support at Zuellig Pharma, the inclusion of the licensed Hangzhou facility marks a significant evolution in the company's ability to support clinical trials in China. He emphasizes that this advancement not only localizes sourcing and distribution capabilities but also enables smoother operation of domestic studies and multi-regional clinical trials (MRCTs) with diminished cycle times and strict adherence to regulatory obligations.
With a proven track record of serving as a trusted clinical logistics and sourcing partner to numerous pharmaceutical giants, Zuellig Pharma's Clinical Trial Support division collaborates with 29 out of the world's top 50 pharmaceutical companies and 18 out of the top 50 global Contract Research Organizations. This highlights the firm’s reputation as a provider of integrated end-to-end clinical supply chain solutions on a global scale.
In summary, Zuellig Pharma's latest acquisition of the Hangzhou facility not only strengthens its infrastructural capabilities but also reiterates the company’s ongoing dedication to building reliable, sustainable, and digitally enhanced clinical supply operations. This strategic move is set to propel the development of innovative medical therapies while improving access to healthcare solutions for regions served by the company. As the healthcare landscape continues to evolve, Zuellig Pharma stands at the forefront, guiding the future of clinical trials and pharmaceutical distribution in Asia and beyond.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.